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The serum of humans and of mice with systemic lupus erythematosus (SLE) 
contains autoantibodies of many specificities, nearly all cell associated (1). The 
preferential  detection  of autoantibodies  to  cellular  antigens  may  not  be  due 
solely to a special predilection to produce such antibodies in SLE, but might be 
also a consequence of in vivo absorption of other autoantibodies by self-antigens 
present in serum in high molar concentrations. Cell-associated autoantigens, in 
contrast, would be either relatively inaccessible to circulating autoantibodies (if 
intracellular)  or  present  in  sufficiently low  serum  concentrations  to escape  in 
vivo absorption. 
To  detect  autoantibody  specificities  that  would  otherwise  be  obscured  in 
serum, modifiedJerne plaque assays were developed to measure cellular secretion 
of antibodies against  common serum  proteins in a  serum-free in vitro system. 
The  results  indicate  that  the  spleens  of autoimmune  mice  of several  strains 
contain  large  numbers  of cells  secreting  autoantibody  to  mouse albumin  and 
transferrin, while these antibodies are present only in small amounts of serum. 
Materials and  Methods 
Mice.  MRL/Mp-lpr/lpr,  MRL/Mp-+/+,  and BXSB mice were from a  colony main- 
tained at the University of North Carolina.  CBA,  B10-congenic, and A-congenic mice 
were obtained from Dr.  Geoffrey Haughton,  University of North Carolina.  NZB mice 
were purchased from The Jackson Laboratory, Bar Harbor, ME. 
Antigens.  Mouse, human, and bovine albumins and human transferrin were purchased 
from Sigma Chemical Co., St. Louis, MO. Mouse, rabbit, hamster, and dog transferrins 
were purchased  from  Cappel  Laboratories, Cochranville,  PA.  Bovine transferrin  was 
obtained from U.S. Biochemical Corp., Cleveland, OH. Ovalbumin was purchased from 
Mann Laboratories, New York. 
Assay  for Antibody-forming Cells.  Cellular secretion of antibody to autologous proteins 
was quantitated using a microtiter  Jerne plaque method (2). Purified mouse proteins were 
attached to sheep erythrocytes (ASA Biologicals, Winston-Salem, NC) using a  chromic 
chloride technique (3, 4). One part of washed, packed erythrocytes was added to one part 
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of protein at a concentration of 1 mg/ml in normal saline. Chromic chloride (Mallinckrodt, 
Inc., St.  Louis,  MO) was then added, generally at  1 mg/ml in normal saline, although 
optimal concentrations were determined empirically for each protein. After  15  min at 
room temperature, the erythrocytes were washed three times before use. The presence 
of protein  on  the  conjugated  erythrocytes was  determined for each batch by passive 
hemagglutination using appropriate goat or rabbit reference antisera against mouse serum, 
mouse transferrin (U.S.  Biochemical Corp.), or human, bovine, dog, or hamster strum 
(Cappel Laboratories). Spleen cells to be assayed for autoantibody plaque-forming cells 
(PFC) were suspended to 1 X 106/ml in Hanks' balanced salt solution (University of North 
Carolina Cancer Center, Chapel Hill, NC).  100 ~1 of cell suspension were mixed with 10 
~1 of 10%  erythrocyte suspension  in  the wells of flat-bottom microtiter plates (Costar, 
Data Packaging, Cambridge, MA) and the plates spun for 10 min at 200 g and then for 5 
min at 400 g. The resulting suspensions of lymphocytes and erythrocytes were allowed to 
incubate for 1 h, at which point was added 10 IA of a 1  : 10 dilution of the IgG fraction of 
a rabbit anti-mouse IgG antiserum, together with sufficient guinea pig complement to 
achieve a final 1:13 concentration. After 1 h incubation at 37 o  C, hemolytic plaques were 
scored with a stereo microscope. Controls, i.e., uncoupled sheep erythrocyte suspensions 
and wells without added lymphocytes, were performed for each experiment to assure that 
plaques were not artifactual. 
Results 
Quantitation of  PFC Against Autologous Proteins.  The spleens of MRL/Mp-lpr/ 
lpr,  BXSB, and  NZB  mice were found to contain substantial  numbers of PFC 
against purified mouse albumin and mouse transferrin (Table I). All antitrans- 
ferrin and  antialbumin  PFC  required  rabbit  anti-mouse  IgG  for visualization 
and thus represented IgG PFC.  In contrast, much smaller numbers were found 
in spleens of mice that did not suffer from autoimmune disease. A  requirement 
for protein synthesis was indicated by the finding that 4-h pretreatment of spleen 
cells with cycloheximide (100 #g/ml) decreased PFC ~85%. 
Table  II  shows  the  numbers  of anti-mouse  transferrin  plaques  observed  in 
MRL/Mp-lpr/lpr mice of varying ages. There was a steady increase in antitrans- 
ferrin plaques  with age,  coincident with  the  development of autoimmunity in 
TABLE  I 
Strain Survey  for PFC Against  Mouse Serum Proteins 
Strain  Age 
PFC per 10  e spleen cells 
Albumin  Transferrin 
mo 
MRL/Mp-lpr/lpr  6  495  2,351 
BXSB  5  293  2,188 
NZB  8  71  1,675 
MRL/Mp-+/+  9  23  210 
B10.D2  18  8  22 
CBA  3  ND  17 
A.BY  3  ND  106 
A.CA  3  ND  58 
A.SW  3  ND  79 
B10.A  3  ND  31 
PFC directed against mouse albumin- or mouse transferrin-coated sheep erythro- 
cytes were  enumerated in a hemolytic plaque assay (see Materials and Methods). The 
small number of PFC directed against sheep erythrocytes was determined in parallel 
assays,  and  has been  subtracted  from  the  data  shown.  Data  represent  a  single 
experiment in which all plaque assays were done simultaneously. The  figures for 
mouse albumin and transferrin PFC are representative of experiments involving 26 
MRL/Mp-lpr/lpr mice and 9  BXSB mice.  10 additional experiments using normal 
mice yielded similar low numbers of PFC. COHEN  ET  AL.  BRIEF  DEFINITIVE  REPORT  1589 
TABLE  II 
Age Dependence  of  Anti-Mouse Transferrin PFC in 
mRL/Mp-lpr/lpr Mice 
Age  PFCper l&spleen cells 
d 
13  213 
56  1,131 
91  2,500 
120  >5,000 
PFC were simultaneously determined  in spleen cell suspensions derived from the 
MRL/Mp-lpr/lpr mice of the indicated ages. Data are from a single experiment in 
which assays  were performed simultaneously. Two similar experiments with lpr mice 
of various ages gave the same results. 
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FIGURE  l.  Data  represent the effect of adding graded amounts of albumin from various 
sources on the number of PFC directed against mouse albumin-coated sheep erythrocytes. 
Simultaneous determination was made of PFC directed against uncoated sheep erythrocytes 
and these (small)  numbers have been subtracted from the data. (0) Mouse albumin; (A)cow 
albumin; (ffl) human albumin; (O) egg albumin. 
these mice. Similar data were obtained with antialbumin PFC in both MRL/Mp- 
lpr/lpr and BXSB mice. 
Specificity of PFC Against  Serum Proteins.  To  determine  whether  the  anti- 
mouse protein  PFC  were  primarily  directed  against  murine  autoantigens,  we 
performed  inhibition  studies.  The  specificity of anti-mouse  albumin  PFC  in 
MRL/Mp-lpr/lpr mice is shown in  Fig.  1.  In this experiment, graded amounts 
of albumin from various species were added to the assay system in an effort to 
inhibit plaques  with  soluble  antigen.  Mouse  albumin  was  the  most  inhibitory 
preparation, followed by cow and human; no inhibition of plaques was seen with 
ovalbumin.  Thus,  antibody secreted  was relatively specific for mouse albumin 
and therefore truly autoreactive. Similar experiments (Fig. 2) were performed 
in the mouse transferrin system. It was noted that, while human transferrin did 
not  inhibit  mouse transferrin  PFC  even  at  concentrations >1  mg/ml,  bovine 
transferrin  was  approximately  equivalent  to  mouse  transferrin  in  inhibiting 
mouse transferrin PFC, indicating crossreactivity between the anti-mouse trans- 
ferrin autoantibody and bovine transferrin. Similar results were obtained when 
bovine transferrin was used on the indicator erythrocytes (not shown). Therefore, 
bovine  transferrin  appeared  to  react  extensively with  mouse  autoantibody to 
transferrin, while human transferrin was not crossreactive. 1590  COHEN  ET  AL.  BRIEF  DEFINITIVE  REPORT 
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FIGURE 2.  Data  represent the effect of adding various concentrations of transferrin derived 
from different species on the number of anti-mouse  transferrin PFC. This is representative 
of two similar experiments. Background PFC against sheep erythrocytes have been subtracted 
as in Fig. 1. 
Comparsion  of  PFC  Against  Foreign  Serum  Proteins  With  Autologous 
PFC.  Polyclonal activation of B cells has been shown to result in formation of 
autoantibodies (5).  If this mechanism contributed to the formation of autoanti- 
bodies to transferrin,  independent of autoantigen,  that it would be anticipated 
that autoantibodies to transferrins of other species would also be produced as a 
consequence of the generalized activation of B  cells. Alternatively, if a  process 
other than global activation of B cells (i.e., an antigen-driven immune response) 
were responsible for the production of anti-mouse transferrin in autoimmune 
mice,  then  relatively  few  PFC  directed  against  heterologous noncrossreactive 
transferrin  would  be seen.  In  Fig.  3,  it  is  seen  that,  while  roughly equivalent 
numbers of PFC were present for the crossreactive mouse and bovine transfer- 
rins, there were few PFC seen against human transferrin.  Rabbit, hamster, and 
dog transferrins, which are partially crossreactive with the mouse autoantibody 
(based  on  their  capacity  to  inhibit  mouse  transferrin  PFC),  when  coupled  to 
sheep red blood cells, were able to detect varying numbers of PFC.  The results 
provide evidence against polyclonai B cell activation as the mechanism ofautoan- 
tibody formation, since PFC were seen mainly against those transferrins known 
to crossreact with the true autoantibody. 
Detection of  Serum Antialbumin and Antitransferrin by ELISA Assay.  Assays were 
developed to detect circulating antibody against mouse albumin and transferrin, 
using  sensitive  enzyme-linked immunosorbent  assay (ELISA) technology.  Sera 
from lpr mice reproducibly gave more binding to mouse albumin- or transferrin- 
coated plates than did normal mouse serum, yet normal samples always contained 
some transferrin-binding immunoglobulin. Extensive efforts were made to inhibit 
the binding both of normal and lpr sera with free transferrin, at concentrations 
as high as  1 mg/ml.  In no case could the binding be inhibited,  indicating that 
the circulating antibody probably was of low avidity. COHEN  ET  AL.  BRIEF  DEFINITIVE  REPORT  1591 
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FIGURE  3.  PFC were enumerated against erythrocytes coated with the indicated transferrins. 
PFC against uncoated erythrocytes, which were negligible, have been subtracted. 
Discussion 
The present data indicate that there is substantial  spontaneous production of 
autoantibody to serum proteins in spleens of autoimmune mice. Although small 
amounts  of such  antibodies  are  detectable  in  the  serum,  the  inability  of free 
antigen to inhibit them indicates that the free antibody is of low avidity. 
The  observation  that  the  autoimmune  mice  produce  antibodies  to  serum 
proteins as well as to cell-bound antigen suggests that autoantibody production 
in murine lupus is a more generalized phenomenon than previously believed and 
that the spectrum of SLE autoantibodies should be widened to include not only 
those directed against constituents of cells, but also those directed against serum 
proteins. The data contrast with recent views (6) that the autoantibodies observed 
in SLE may represent a  much more limited repertoire of molecules with inter- 
esting polyspecificities. 
The  present  study also shows that  the  autoantibodies  detected here  at  the 
cellular level are relatively specific for autologous proteins. The hypothesis that 
autoantibody  production  in  those  strains  is  merely  a  consequence  of diffuse 
polyclonal B cell activation cannot explain these findings, since one would then 
anticipate equivalent production of antibodies to transferrins of different species. 
Furthermore,  while  it  is  true  that  the  production  of polyclonal antibodies  to 
many exogenous antigens  is characteristic  of murine  lupus, such antibodies are 
generally elevated only two- or threefold (7). For both quantitative and qualitative 
reasons,  such  a  global increase  in antibody production  would not explain  the 
production  of autoantibodies  to  serum  proteins  that  are  specifically directed 
against autologous serum proteins. The mechanism responsible must be able to 
cause  general  production  of autoantibodies  that  are  specific  for  the  species. 
These data are best explained by assuming that  autoantigens  themselves drive 
the autoantibody response and that, in the presence of a regulatory abnormality, 
the production of each individual autoantibody is due to antigen-specific events 
rather  than  diffuse activation  of B cells by polyclonal B cell activators of T  or 
non-T cell origin. 
Since the autoantibodies against serum proteins described herein are probably 
incorporated into immune complexes shortly after antibody secretion because of 
the  availability of antigen,  such complexes may be involved  in  the genesis  of 
giomerular injury and other immune complex effects. In addition,  it is possible 
that  some species of transferrin  autoantibodies  interfere  with  iron binding,  or 
with  the  cell  growth-regulating  properties  of transferrin,  and  thus  possibly 
contribute to anemia or disordered cell replication in SLE. 1592  COHEN  ET  AL.  BRIEF  DEFINITIVE  REPORT 
Summary 
The autoantibodies found in human and murine systemic lupus erythematosus 
(SLE) are generally directed against cells or components of cells such as nuclear 
antigens. This predilection may be due to the unusual immunogenicity of certain 
autoantigens, or to unusual patterns of antibody crossreactivity. Alternatively, 
the observed spectrum of reactivities may reflect the in vivo absorption of those 
autoantibodies directed against soluble antigens. To  test whether hitherto  un- 
detected autoantibodies against serum proteins might exist in murine SLE, we 
developed  assays  that  were  independent  of  the  possibility  of absorption  of 
autoantibodies by serum  autoantigens;  large  numbers  of plaque-forming cells 
(PFC) directed against mouse albumin and mouse transferrin were easily detected 
in  the spleens of MRL/Mp-lpr/lpr,  BXSB,  and  NZB  mice. The  secreted anti- 
bodies were relatively specific for the mouse proteins,  since only limited cross- 
reactivity was seen with albumin and transferrins of other species in inhibition 
experiments. The production of these hidden antibodies could not be the result 
of diffuse polyclonal B cell activation, since the PFC to mouse transferrins and 
albumin were not always accompanied by comparable numbers of PFC against 
related albumins and transferrins.  The results indicate that autoantibody pro- 
duction  in  murine  lupus  is  a  generalized  phenomenon,  not  limited  to  the 
production ofautoantibodies to nuclear or other cell-bound antibodies. However, 
the relative specificity of the autoantibodies for self-antigens indicates that diffuse 
polyclonal B  cell activation  cannot be  the  mechanism responsible,  and argues 
that a selective mechanism, probably driven by antigen, accounts for production 
of autoantibodies in SLE. 
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